-
1
-
-
2542561964
-
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer
-
DOI 10.1056/NEJMoa032691
-
Hurwitz H, Fehrenbacher L, Novotny W et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004; 350(23) 2335-2342. (Pubitemid 38702844)
-
(2004)
New England Journal of Medicine
, vol.350
, Issue.23
, pp. 2335-2342
-
-
Hurwitz, H.1
Fehrenbacher, L.2
Novotny, W.3
Cartwright, T.4
Hainsworth, J.5
Heim, W.6
Berlin, J.7
Baron, A.8
Griffing, S.9
Holmgren, E.10
Ferrara, N.11
Fyfe, G.12
Rogers, B.13
Ross, R.14
Kabbinavar, F.15
-
2
-
-
42949149159
-
Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer, a randomized phase III study
-
Saltz LB, Clarke S, Díaz-Rubio E et al. Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer, a randomized phase III study. J Clin Oncol 2008; 26(12): 2013-2019.
-
(2008)
J Clin Oncol
, vol.26
, Issue.12
, pp. 2013-2019
-
-
Saltz, L.B.1
Clarke, S.2
Díaz-Rubio, E.3
-
3
-
-
68949094312
-
Improved survival in metastatic colorectal cancer is associated with adoption of hepatic resection and improved chemotherapy
-
Kopetz S, Chang GJ, Overman MJ et al. Improved survival in metastatic colorectal cancer is associated with adoption of hepatic resection and improved chemotherapy. J Clin Oncol 2009; 27(22): 3677-3683.
-
(2009)
J Clin Oncol
, vol.27
, Issue.22
, pp. 3677-3683
-
-
Kopetz, S.1
Chang, G.J.2
Overman, M.J.3
-
4
-
-
79959338988
-
Survival for metastatic colorectal cancer in the bevacizumab era: A population-based analysis
-
Renouf DJ, Lim HJ, Speers C et al. Survival for metastatic colorectal cancer in the bevacizumab era: a population-based analysis. Clin Colorectal Cancer 2011; 10(2): 97-101.
-
(2011)
Clin Colorectal Cancer
, vol.10
, Issue.2
, pp. 97-101
-
-
Renouf, D.J.1
Lim, H.J.2
Speers, C.3
-
5
-
-
70349413045
-
Investigators of the BRiTE study Clinical outcomes associated with bevacizumab-containing treatment of metastatic colorectal cancer: The BRiTE observational cohort study
-
Kozloff M, Yood MU, Berlin J et al. Investigators of the BRiTE study Clinical outcomes associated with bevacizumab-containing treatment of metastatic colorectal cancer: the BRiTE observational cohort study. Oncologist 2009; 14(9): 862-870.
-
(2009)
Oncologist
, vol.14
, Issue.9
, pp. 862-870
-
-
Kozloff, M.1
Yood, M.U.2
Berlin, J.3
-
6
-
-
3242720345
-
Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan- refractory metastatic colorectal cancer
-
DOI 10.1056/NEJMoa033025
-
Cunningham D, Humblet Y, Siena S et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 2004; 351(4): 337-345. (Pubitemid 38944402)
-
(2004)
New England Journal of Medicine
, vol.351
, Issue.4
, pp. 337-345
-
-
Cunningham, D.1
Humblet, Y.2
Siena, S.3
Khayat, D.4
Bleiberg, H.5
Santoro, A.6
Bets, D.7
Mueser, M.8
Harstrick, A.9
Verslype, C.10
Chau, I.11
Van Cutsem, E.12
-
7
-
-
34147103678
-
Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy- refractory metastatic colorectal cancer
-
Van Cutsem E, Peeters M, Siena S et al. Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer. J Clin Oncol 2007; 25(13): 1658.
-
(2007)
J Clin Oncol
, vol.25
, Issue.13
, pp. 1658
-
-
Van Cutsem, E.1
Peeters, M.2
Siena, S.3
|